🧬 Genetic Disorder

Hereditary Hemochromatosis

Also known as: HFE-related hemochromatosis, Primary hemochromatosis, Iron overload disease

Hereditary hemochromatosis is a genetic disorder characterized by excessive iron absorption from the diet, leading to iron accumulation in the body's organs, particularly the liver, heart, and pancreas. If left untreated, this iron overload can cause significant organ damage and dysfunction.

👥 1 in 200 to 1 in 400 individuals of Northern European descent Prevalence
🔬 30 Active Trials

Imagine your body is like a piggy bank that's collecting too much iron. This extra iron can hurt your liver, heart, and other body parts. Doctors can help by taking out some of the iron, like emptying the piggy bank a little bit at a time.

Signs & Symptoms

  • Fatigue
  • Joint pain
  • Abdominal pain
  • Liver enlargement
  • Skin pigmentation (bronzing)
  • Diabetes
  • Heart problems (cardiomyopathy, arrhythmias)
  • Erectile dysfunction
  • Arthritis

Treatment Options

THERAPY FDA Approved

Phlebotomy (blood removal)

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Iron chelation therapy (e.g., deferoxamine, deferasirox, deferiprone)

MODERATELY EFFECTIVE
SUPPORTIVE

Dietary modifications (avoiding iron-rich foods and supplements)

SUPPORTIVE
SUPPORTIVE FDA Approved

Treatment of complications (e.g., diabetes management, heart failure treatment)

SUPPORTIVE

Diagnosis

  • Serum iron studies (serum iron, total iron-binding capacity, transferrin saturation)
  • Ferritin level
  • Genetic testing for HFE gene mutations (C282Y, H63D)
  • Liver biopsy (to assess iron levels and liver damage)
  • MRI (to assess iron overload in organs)

History

Hemochromatosis was first described in the late 19th century, but its genetic basis was not understood until the discovery of the HFE gene in 1996. This discovery revolutionized the diagnosis and management of the disease, allowing for earlier detection and prevention of complications.

Recent Breakthroughs

2022

Novel Biomarkers for Early Detection of Liver Fibrosis in Hemochromatosis

Research identified new serum biomarkers that can predict the development of liver fibrosis in patients with hemochromatosis, potentially allowing for earlier intervention and prevention of advanced liver disease.

2023

Improved Iron Chelation Therapies with Reduced Side Effects

Clinical trials have shown that newer formulations of iron chelators have improved efficacy and fewer side effects compared to traditional chelation therapies, enhancing patient compliance and treatment outcomes.